Sigrima 420mg Injection: Advanced HER2-Targeted Therapy for Breast Cancer
Are you searching for a reliable Sigrima 420mg Injection exporter from India? Ernest Oncology, a premier division of Ernest Pharmaceutical Pvt. Ltd., is a globally recognized supplier and bulk distributor of specialized biologics. We maintain a high-authority, regulatory-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving monoclonal antibodies reach healthcare facilities with pharmaceutical-grade integrity and efficient global logistics.
Detailed Product Overview: What is Sigrima 420mg?
Sigrima 420mg is a high-potency intravenous injection containing the active pharmaceutical ingredient Pertuzumab.
Manufactured by Zydus Lifesciences Ltd., Sigrima 420mg is a world-class biosimilar to the innovator brand Perjeta.
Primary Therapeutic Indications
Sigrima 420 mg Injection is clinically indicated for the management of
HER2-Positive Metastatic Breast Cancer: Used in combination with trastuzumab and docetaxel for patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Neoadjuvant Treatment: Administered before surgery in patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer to shrink tumors.
Adjuvant Treatment: Used after surgery for patients with early-stage HER2-positive breast cancer who are at a high risk of recurrence.
Mechanism of Action: How Sigrima 420mg Works
Sigrima (Pertuzumab) utilizes a sophisticated "Dual Blockade" approach when used with other therapies:
HER2 Dimerization Inhibition: It specifically targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 (HER2).
Blocking Signals: By binding to this site, Sigrima prevents HER2 from pairing (dimerizing) with other HER family receptors (HER1, HER3, and HER4).
This pairing is the "switch" that sends growth signals to cancer cells. Apoptosis & Immune Response: Blocking these signals stops cell proliferation and induces apoptosis (cell death).
It also mediates antibody-dependent cell-mediated cytotoxicity (ADCC), prompting the immune system to attack cancer cells.
Administration and Safety Guidelines
Dosage: Administered as an intravenous (IV) infusion.
The standard loading dose is typically 840mg, followed by a maintenance dose of 420mg every three weeks. Medical Supervision: This medication must only be administered by a qualified healthcare professional in a clinical setting.
Key Precautions:
Left Ventricular Dysfunction: Pertuzumab can affect heart function; regular LVEF (Left Ventricular Ejection Fraction) monitoring is required.
Infusion-Related Reactions: Patients should be monitored for fever, chills, or rashes during and after the infusion.
Embryo-Fetal Toxicity: Sigrima can cause fetal harm.
Effective contraception is mandatory during treatment and for 7 months after the final dose. Storage: Must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F).
Do not freeze or shake.
Why Source Sigrima 420 mg from Ernest Oncology?
Verified Indian Exporter: Authentic supply from Zydus Lifesciences, ensuring 100% product integrity and competitive wholesale pricing.
Global Logistics Mastery: Deep expertise in navigating the specialized regulatory landscapes of the USA, UK, Australia, and South Africa.
Cold-Chain Excellence: We utilize validated temperature-controlled packaging to ensure the biochemical stability of monoclonal antibodies during international transit.
B2B Reliability: We specialize in fulfilling large-scale orders for oncology centers, government tenders, and regional distributors.
📞 Contact Ernest Oncology — Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.]
🌐 Websites:
📧 Email:
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
